At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ODD ODDITY Tech Ltd.
Market Closed 10-23 16:00:00 EDT
22.65
-0.70
-3.00%
盘后22.65
+0.000.00%
19:53 EDT
High23.39Low22.60Vol461.20K
Open23.02D1 Closing23.35Amplitude3.40%
Mkt Cap1.04BTradable Cap647.47MTotal Shares46.12M
T/O10.56MT/O Rate1.61%Tradable Shares28.59M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
GlobeNewswire  ·  10-20
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
Moomoo Extends Options Trading Hours* with Pre-Market and Post-Close Sessions
GlobeNewswire  ·  10-19
Moomoo Extends Options Trading Hours* with Pre-Market and Post-Close Sessions
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
GlobeNewswire  ·  10-19
Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
GlobeNewswire  ·  10-16
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Laureate Education (LAUR), ODDITY Tech Ltd. Class A (ODD) and Celsius Holdings (CELH)
TIPRANKS  ·  10-15
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Laureate Education (LAUR), ODDITY Tech Ltd. Class A (ODD) and Celsius Holdings (CELH)
ODDITY Tech (ODD) Seeks Dismissal of Securities Lawsuit Over Advertising Algorithm Disclosures
TIPRANKS  ·  10-15
ODDITY Tech (ODD) Seeks Dismissal of Securities Lawsuit Over Advertising Algorithm Disclosures
Discover Power Solutions International And 2 More Leading Growth Stocks With Insider Ownership
Simply Wall St.  ·  10-12
Discover Power Solutions International And 2 More Leading Growth Stocks With Insider Ownership
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
GlobeNewswire  ·  10-12
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  10-05
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire  ·  10-01
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
GlobeNewswire  ·  09-30
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire  ·  09-29
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
GlobeNewswire  ·  09-29
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
GlobeNewswire  ·  09-28
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
Court Grants Motion to Dismiss Oddity Tech (ODD) Securities Lawsuit, Finding Material Misstatements Were Not Adequately Pleaded
TIPRANKS  ·  09-24
Court Grants Motion to Dismiss Oddity Tech (ODD) Securities Lawsuit, Finding Material Misstatements Were Not Adequately Pleaded
Goldman Sachs Sticks to Its Sell Rating for ODDITY Tech Ltd. Class A (ODD)
TIPRANKS  ·  09-14
Goldman Sachs Sticks to Its Sell Rating for ODDITY Tech Ltd. Class A (ODD)
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
GlobeNewswire  ·  09-14
WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
ODDITY Tech Earnings Call: Growth Brands vs Ad Shock
TIPRANKS  ·  09-12
ODDITY Tech Earnings Call: Growth Brands vs Ad Shock
Oddity Tech Price Target Raised to $18.00/Share from $16.00 by Jefferies
Dow Jones  ·  09-10
Oddity Tech Price Target Raised to $18.00/Share from $16.00 by Jefferies
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Delfi (OtherPEFDF) and ODDITY Tech Ltd. Class A (ODD)
TIPRANKS  ·  09-10
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Delfi (OtherPEFDF) and ODDITY Tech Ltd. Class A (ODD)

Introduction

Company Name.
ODDITY Tech Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.
Issue price:
--